COVID-19是一种影响整个世界的疾病,它继续传播新的变体。患者的先天免疫系统在COVID-19的轻度和重度转变中起关键作用。抗菌肽(AMP),它们是先天免疫系统的重要组成部分,是对抗致病菌的潜在分子,真菌,和病毒。人β-防御素2(hBD-2),一种41个氨基酸的抗菌肽,是一种在皮肤中诱导表达的防御素,肺,和人类的气管。在这项研究中,目的研究在体外条件下在毕赤酵母中重组产生的hBD-2与人血管紧张素转换酶2(ACE-2)的相互作用。首先,通过pPICZαA载体将hBD-2克隆到巴斯德毕赤酵母X-33中,酵母表达平台,并通过SDS-PAGE确认其表达,西方印迹,和qRT-PCR。然后,重组hBD-2和ACE-2蛋白之间的相互作用通过下拉法得到揭示。根据这些初步实验,我们建议重组产生的hBD-2可能对SARS-CoV-2具有保护作用,并可作为治疗的补充。然而,目前的发现需要细胞培养研究的支持,毒性分析,和体内实验。
COVID-19 is a disease that have affected the entire world, and it continues to spread with new variants. A patient\'s innate immune system plays a critical role in the mild and severe transition of COVID-19. Antimicrobial peptides (AMPs), which are important components of the innate immune system, are potential molecules to fight pathogenic bacteria, fungi, and viruses. Human β-defensin 2 (hBD-2), a 41-amino-acid antimicrobial peptide, is one of the defensins inducibly expressed in the skin, lungs, and trachea in humans. In this study, it was aimed to investigate the interaction of hBD-2 produced recombinantly in Pichia pastoris with the human angiotensin-converting enzyme 2 (ACE-2) under in vitro conditions. First, hBD-2 was cloned in P. pastoris X-33 via the pPICZαA vector, a yeast expression platform, and its expression was confirmed by SDS-PAGE, western blotting, and qRT-PCR. Then, the interaction between recombinant hBD-2 and ACE-2 proteins was revealed by a pull-down assay. In light of these preliminary experiments, we suggest that the recombinantly produced hBD-2 may be protective against SARS-CoV-2 and be used as a supplement in treatment. However, current findings need to be supported by cell culture studies, toxicity analyses, and in vivo experiments.